Five new 'Key Opinion Leaders' appointed to blinkcns scientific advisory board

CHARLESTON, S.C. - March 30, 2021 - PRLog -- Blinkcns, Inc, a biotechnology company pioneering blink reflex technology intended to improve the detection, differentiation, and management of neurological disease and conditions, announced today that they have appointed five new Key Opinion Leaders (KOLs) to their scientific advisory board.

The KOLs will lend their expertise to help steer the company's research of diseases and conditions of the central nervous system (CNS) such as Parkinson's disease, Alzheimer's disease/dementia and migraine and the rolethe blink reflex may play in the early detection and management of each.

The new KOLs are respected industry leaders including:

• Angelo Antonini, MD, PhD, director of the Parkinson's Dept. at the Institute of Neurology, IRCCS San Camillo, Venice;
• Matteo Bologna, MD, PhD, researcher at Sapienza University of Rome Department of Neurology and Psychiatry in Rome, Italy;
• Roy Jones, BSc (Hons), MBBS, Dip Pharm Med, professor of clinical gerontology and director at the Research Institute for the Care of the Elderly in Bath, England;
• Fidias Leon-Sarmiento, MD, PhD, senior research investigator at the University of Pennsylvania's Perelman School of Medicine in State College, Pennsylvania; and
• Fabrizio Stocchi, MD, PhD, director of the Parkinson's Disease and Movement Disorders Research Centre in Rome, Italy;

"We are honored to add some of the world's leading minds in diseases of the central nervous system to the scientific advisory board," said Blinkcns CEO Jeff Riley. "These experts bring decades of unmatched experience in our main research areas, which will prove to be essential for the advancement of our scientific research and development, study design and implementation, and technology. We are proud to call upon these respected thought leaders to help provide scientific strategic direction and serve as advocates of our company."

About Blinkcns
Blinkcns is a biotechnology company dedicated to improving the detection, differentiation, and management of neurological disease through rapid, noninvasive collection of objective data from the eyes. Blinkcns has the world's first FDA-cleared patented device, called EyeStat, that provides fast, objective data about the blink reflex, a component of the startle response. EyeStat deploys eight light puffs of air across a patient's eyelashes to stimulate their blink reflex in a 30-second test. The system uses high-speed videography to capture and record the eyelids and measure 10 physiological parameters of the blink reflex using a proprietary algorithm. Blinkcns continues to research and apply its technology to several neurological states and conditions such as Parkinson's disease, Alzheimer's disease / dementia, and migraine. Learn more at https://www.blinkcns.com.